SG11201901294QA - Sustained-release buprenorphine formulations background of invention - Google Patents
Sustained-release buprenorphine formulations background of inventionInfo
- Publication number
- SG11201901294QA SG11201901294QA SG11201901294QA SG11201901294QA SG11201901294QA SG 11201901294Q A SG11201901294Q A SG 11201901294QA SG 11201901294Q A SG11201901294Q A SG 11201901294QA SG 11201901294Q A SG11201901294Q A SG 11201901294QA SG 11201901294Q A SG11201901294Q A SG 11201901294QA
- Authority
- SG
- Singapore
- Prior art keywords
- international
- xinyi
- aly
- dist
- taiwan
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/485—Morphinan derivatives, e.g. morphine, codeine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/20—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing sulfur, e.g. dimethyl sulfoxide [DMSO], docusate, sodium lauryl sulfate or aminosulfonic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/36—Opioid-abuse
Abstract
INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property 111111101111 0 1110101011111 011101 0 011111111111111111111011111111111110111111 Organization International Bureau (10) International Publication Number (43) International Publication Date ......0\" WO 2018/050043 Al 22 March 2018 (22.03.2018) WIP0 I PCT (51) International Patent Classification: TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, A61K 31/485 (2006.01) A61K 47/22 (2006.01) KM, ML, MR, NE, SN, TD, TG). A61K 9/08 (2006.01) A61P 25/36 (2006.01) A61K 47/10 (2006.01) A61P 25/04 (2006.01) Published: (21) International Application Number: — with international search report (Art. 21(3)) PCT/CN2017/101327 (22) International Filing Date: 12 September 2017 (12.09.2017) (25) Filing Language: English (26) Publication Language: English (30) Priority Data: 62/394,168 13 September 2016 (13.09.2016) US (71) Applicant: ALAR PHARMACEUTICALS INC. [CN/CN]; No. 3, Aly. 27, Ln. 30, Sec. 4, Xinyi Rd., Da'an Dist., Taipei City, Taiwan 106 (CN). (72) Inventors: LIN, Tong-Ho; No. 3, Aly. 27, Ln. 30, Sec. 4, Xinyi Rd., Da'an Dist., Taipei City, Taiwan 106 (CN). WEN, Yung-Shun; No. 3, Aly. 27, Ln. 30, Sec. 4, Xinyi Rd., Da'an Dist., Taipei City, Taiwan 106 (CN). LIANG, Jui-Wei; No. 3, Aly. 27, Ln. 30, Sec. 4, Xinyi Rd., Da'an Dist., Taipei City, Taiwan 106 (CN). Agent: SHANGHAI PATENT & TRADEMARK LAW = (74) OFFICE, LLC; 435 Guiping Road, Shanghai 200233 (CN). Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW. (81) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, (84) 1-1 M 71- (54) Title: SUSTAINED-RELEASE BUPRENORPHINE FORMULATIONS BACKGROUND OF INVENTION 0 0 (57) : An injectable pharmaceutical composition includes a solution of 3-acyl-buprenorphine, or a pharmaceutically acceptable It In salt thereof, in a biocompatible organic solvent, wherein the injectable pharmaceutical composition exhibits a steady release profile last- = ing over one week when injected into a patient. The acyl group is an alkylcarbonyl group, and an alkyl portion of the alkylcarbonyl group ww is a straight-chain, branched-chain, having 1-20 carbon atoms. The biocompatible organic solvent is N-methyl-2-pyrrolidone, ethyl 1-1 © acetate, ethanol, butanol, 2-butanol, isobutanol, ispropanol, glycerin, benzyl benzoate, dimethyl sulfoxide, N, N-dimethylacetamide, f'1 propylene glycol, dimethyl glycol, benzyl alcohol, or a combination of two or more thereof. C
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662394168P | 2016-09-13 | 2016-09-13 | |
| PCT/CN2017/101327 WO2018050043A1 (en) | 2016-09-13 | 2017-09-12 | Sustained-release buprenorphine formulations background of invention |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG11201901294QA true SG11201901294QA (en) | 2019-03-28 |
Family
ID=61619029
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11201901294QA SG11201901294QA (en) | 2016-09-13 | 2017-09-12 | Sustained-release buprenorphine formulations background of invention |
Country Status (30)
| Country | Link |
|---|---|
| US (1) | US10744132B2 (en) |
| EP (1) | EP3512518B1 (en) |
| JP (1) | JP6929367B2 (en) |
| KR (1) | KR102244500B1 (en) |
| CN (1) | CN109789137B (en) |
| AR (1) | AR110468A1 (en) |
| AU (1) | AU2017325910B2 (en) |
| BR (1) | BR112019004923A2 (en) |
| CA (1) | CA3033046C (en) |
| CL (1) | CL2019000624A1 (en) |
| CO (1) | CO2019003632A2 (en) |
| DK (1) | DK3512518T3 (en) |
| ES (1) | ES2934721T3 (en) |
| FI (1) | FI3512518T3 (en) |
| HR (1) | HRP20230062T8 (en) |
| HU (1) | HUE060906T2 (en) |
| LT (1) | LT3512518T (en) |
| MX (1) | MX2019002675A (en) |
| MY (1) | MY196269A (en) |
| PE (1) | PE20190707A1 (en) |
| PH (1) | PH12019500466A1 (en) |
| PL (1) | PL3512518T3 (en) |
| PT (1) | PT3512518T (en) |
| RS (1) | RS63894B1 (en) |
| RU (1) | RU2747306C2 (en) |
| SG (1) | SG11201901294QA (en) |
| SI (1) | SI3512518T1 (en) |
| TW (1) | TWI743193B (en) |
| WO (1) | WO2018050043A1 (en) |
| ZA (1) | ZA201900890B (en) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1057075C (en) * | 1997-09-10 | 2000-10-04 | 中国石油化工总公司 | Process for producing low carbon alcohol by directly hydrating low carbon olefines |
| US11524965B2 (en) * | 2018-05-11 | 2022-12-13 | Alar Pharmaceuticals Inc. | Long-acting injectable formulations and crystalline forms of buprenorphine derivatives |
| BR112021012210A2 (en) * | 2018-12-27 | 2021-08-31 | Alar Pharmaceuticals Inc. | NALTREXONE SUSTAINED RELEASE INJECT FORMULATION |
Family Cites Families (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE60015370T2 (en) | 1999-08-27 | 2006-03-09 | Southern Research Institute, Birmingham | INJECTABLE BUPRENORPHINIC MICROSPHERIC COMPOSITIONS AND THEIR USE IN REDUCING HEROINE AND ALCOHOL CONSUMPTION |
| ATE444296T1 (en) | 2002-10-25 | 2009-10-15 | Euro Celtique Sa | ANALOGUE AND PRODRUGS OF BUPRENORPHINE |
| TWI226830B (en) * | 2002-11-12 | 2005-01-21 | Chi Mei Foundation Medical Ct | Novel ester derivatives of buprenorphine and their preparation processes, and long acting analgesic pharmaceutical compositions |
| CN1263760C (en) * | 2002-11-12 | 2006-07-12 | 财团法人奇美医院 | Novel buprenorphine ester derivatives and process for preparing the same and medical compounds with long-acting analgesic effect |
| ATE382050T1 (en) * | 2002-11-25 | 2008-01-15 | Chi Mei Foundation Medical Ct | BUPRENORPHINE ESTER DERIVATIVES, METHOD FOR THE PRODUCTION THEREOF, AND LONG-ACTING ANALGESIC DRUGS |
| DK1768650T3 (en) | 2004-06-04 | 2008-09-29 | Camurus Ab | Liquid storage formulations |
| BRPI0618891A2 (en) * | 2005-11-21 | 2011-09-13 | Schering Plough Ltd | pharmaceutical compositions |
| GB0606124D0 (en) * | 2006-03-28 | 2006-05-03 | Reckitt Benckiser Healthcare | Buprenorphine derivatives and uses thereof |
| CA2663515C (en) * | 2006-09-22 | 2015-09-01 | Alltranz Inc. | Transdermally deliverable buprenorphine prodrugs and abuse-resistant compositions thereof |
| US20090181068A1 (en) * | 2008-01-14 | 2009-07-16 | Dunn Richard L | Low Viscosity Liquid Polymeric Delivery System |
| GB2513060B (en) | 2010-06-08 | 2015-01-07 | Rb Pharmaceuticals Ltd | Microparticle buprenorphine suspension |
| GB2481018B (en) * | 2010-06-08 | 2015-03-18 | Rb Pharmaceuticals Ltd | Injectable flowable composition comprising buprenorphine |
| FR2975912B1 (en) * | 2011-05-30 | 2013-06-14 | Flamel Tech Sa | CONTROLLED RELEASE COMPOSITION OF BUPRENORPHINE |
| US9393211B2 (en) | 2013-03-15 | 2016-07-19 | Oakwood Laboratories LLC | High drug load buprenorphine microspheres and method of producing same |
| GB201404139D0 (en) * | 2014-03-10 | 2014-04-23 | Rb Pharmaceuticals Ltd | Sustained release buprenorphine solution formulations |
| GB201419091D0 (en) * | 2014-10-27 | 2014-12-10 | Camurus Ab | Formulations |
-
2017
- 2017-09-12 BR BR112019004923A patent/BR112019004923A2/en active Search and Examination
- 2017-09-12 CA CA3033046A patent/CA3033046C/en active Active
- 2017-09-12 TW TW106131215A patent/TWI743193B/en active
- 2017-09-12 MX MX2019002675A patent/MX2019002675A/en active IP Right Grant
- 2017-09-12 MY MYPI2019000910A patent/MY196269A/en unknown
- 2017-09-12 EP EP17850245.6A patent/EP3512518B1/en active Active
- 2017-09-12 PT PT178502456T patent/PT3512518T/en unknown
- 2017-09-12 CN CN201780055635.3A patent/CN109789137B/en active Active
- 2017-09-12 PL PL17850245.6T patent/PL3512518T3/en unknown
- 2017-09-12 KR KR1020197009185A patent/KR102244500B1/en active IP Right Grant
- 2017-09-12 JP JP2019535434A patent/JP6929367B2/en active Active
- 2017-09-12 ES ES17850245T patent/ES2934721T3/en active Active
- 2017-09-12 HR HRP20230062TT patent/HRP20230062T8/en unknown
- 2017-09-12 FI FIEP17850245.6T patent/FI3512518T3/en active
- 2017-09-12 AU AU2017325910A patent/AU2017325910B2/en active Active
- 2017-09-12 DK DK17850245.6T patent/DK3512518T3/en active
- 2017-09-12 US US16/098,864 patent/US10744132B2/en active Active
- 2017-09-12 PE PE2019000487A patent/PE20190707A1/en unknown
- 2017-09-12 RS RS20230034A patent/RS63894B1/en unknown
- 2017-09-12 RU RU2019102895A patent/RU2747306C2/en active
- 2017-09-12 SI SI201731295T patent/SI3512518T1/en unknown
- 2017-09-12 SG SG11201901294QA patent/SG11201901294QA/en unknown
- 2017-09-12 LT LTEPPCT/CN2017/101327T patent/LT3512518T/en unknown
- 2017-09-12 HU HUE17850245A patent/HUE060906T2/en unknown
- 2017-09-12 WO PCT/CN2017/101327 patent/WO2018050043A1/en unknown
- 2017-09-13 AR ARP170102519A patent/AR110468A1/en unknown
-
2019
- 2019-02-12 ZA ZA2019/00890A patent/ZA201900890B/en unknown
- 2019-03-01 PH PH12019500466A patent/PH12019500466A1/en unknown
- 2019-03-12 CL CL2019000624A patent/CL2019000624A1/en unknown
- 2019-04-11 CO CONC2019/0003632A patent/CO2019003632A2/en unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| SG11201906891RA (en) | Methods for the administration of certain vmat2 inhibitors | |
| SG11201909168VA (en) | Combination comprising a ppar agonist such as elafibranor and an acetyl-coa carboxylase (acc) inhibitor | |
| SG11201808907PA (en) | Inhibitors of activin receptor-like kinase | |
| SG11201809714TA (en) | Piperidines as menin inhibitors | |
| SG11201811338VA (en) | A novel botulinum neurotoxin and its derivatives | |
| SG11201809299QA (en) | Formulations of an lsd1 inhibitor | |
| SG11201902938TA (en) | Compounds, devices, and uses thereof | |
| SG11201811150WA (en) | Ev-mediated delivery of binding protein-small molecule conjugates | |
| SG11201807784SA (en) | 3-desoxy derivative and pharmaceutical compositions thereof | |
| SG11201909155VA (en) | Ask1 inhibitor compounds and uses thereof | |
| SG11201809688RA (en) | Use of topical formulations of cannabinoids in the treatment of epidermolysis bullosa and related connective tissue disorders | |
| SG11201810280YA (en) | Spiro-lactam nmda receptor modulators and uses thereof | |
| SG11201900558RA (en) | Spiro-lactam nmda receptor modulators and uses thereof | |
| SG11201808949SA (en) | Combinations and methods comprising a capsid assembly inhibitor | |
| SG11201809499UA (en) | Processes for preparing phosphorodiamidate morpholino oligomers | |
| SG11201903326RA (en) | Liposomal formulation for use in the treatment of cancer | |
| SG11201804223TA (en) | OCTAHYDROPYRROLO [3, 4-c] PYRROLE DERIVATIVES AND USES THEREOF | |
| SG11201900551WA (en) | Spiro-lactam nmda receptor modulators and uses thereof | |
| SG11201900546UA (en) | Spiro-lactam and bis-spiro-lactam nmda receptor modulators and uses thereof | |
| SG11201810429UA (en) | Anti-cd19 antibody formulations | |
| SG11201900238UA (en) | Compounds and methods for modulation of smn2 | |
| SG11201906164RA (en) | Bicyclic inhibitors of histone deacetylase | |
| SG11201901294QA (en) | Sustained-release buprenorphine formulations background of invention | |
| SG11201906922TA (en) | Processes for preparing ag-10, its intermediates, and salts thereof | |
| SG11201901048VA (en) | Pharmaceutical compositions and uses directed to lysosomal storage disorders |